“Without clinical research, there would be little if any development of new medicines,” says Isabelle Schenkenberger, MD. “I’m proud and excited to be a part of it.” Dr. Schenkenberger is especially proud of her clinical trial research work in heart health, noting most new drugs never make it to market. She’s been involved in several … Read more
Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, is the lead author of an article recently published in the New England Journal of Medicine. The article highlights the results of a Phase 3 trial of elafibranor for the treatment primary biliary cholangitis, an autoimmune disease that causes inflammation and damage of the bile ducts in the … Read more
Velocity is proud to announce the MASH Council to Accelerate Research Excellence (CARE). Led by Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, and Nadege Gunn, MD, CPI, the MASH CARE Council will help drive world-class operational, recruitment, and trial conduct oversight for the 20+ Velocity sites conducting liver disease research — including both metabolic dysfunction-associated … Read more
Paul Evans was recently named CEO of the Year in the Middle Market Division by Business North Carolina! He, along with his fellow awardees in the Enterprise and Growth categories, were celebrated last month at the annual CEO Summit. Since moving to North Carolina in 2018, Paul has led Velocity to achieve dramatic growth. This … Read more
Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, was the lead author of an article recently published in The Lancet Gastroenterology & Hepatology. Dr. Kowdley and team conducted a Phase 2 trial investigating the efficacy of rusfertide in treating HFE-related haemochromatosis (an inherited iron overload disorder caused by insufficient hepcidin production). Rusfertide prevented iron re-accumulation in … Read more
Velocity Clinical Research, the leading multi-specialty clinical sites business, announced it has acquired Impact Research Institute (Waco, TX) and the clinical trials unit of Liver Institute Northwest (Seattle, WA), aggressively expanding its capabilities in liver disease research, including MASH (metabolic dysfunction-associated steatohepatitis) and MASLD (metabolic dysfunction-associated steatotic liver disease). According to the NASH education program, … Read more
Julio Rosenstock, MD, FACE, Principal Investigator at Velocity and the leader of the Diabetes and Obesity CARE Council, unveiled data suggesting a potential breakthrough for adults with prediabetes. When administered oral semaglutide, trial participants achieved normoglycemia at 68 weeks. Dr. Rosenstock commented, “Those people who participated in the OASIS 1 trial with prediabetes who received … Read more
Shiva Muthiah, Director of UK Operations for Velocity, smiles as she recalls the triumph of a teenage patient battling a painful eczema skin condition. “He used to wear long sleeves and other clothing designed to hide the marks on his skin, but almost immediately after beginning treatment in our clinical trial, the improvement was dramatic … Read more
Velocity is proud to unveil another groundbreaking initiative: the Cardiology Council to Accelerate Research Excellence (CARE). Headed by William Cromwell, MD, FAHA, FNLA and Steven Martin, MD, FACC, the Cardiology CARE Council will support strategic partnerships with Sponsors and CROs, backed by Velocity’s extensive track record of success in cardiology clinical trials. Heart disease remains … Read more
Velocity has won the 2023 SCRS Excellence in Patient Centricity Award. The award was presented to the Velocity team at the 2023 Global Site Solutions Summit in Hollywood, FL. This award recognizes an organization that has “proven its commitment to effective patient engagement by understanding clinical research from the patient perspective. Through the consideration of … Read more